Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries.

Autor:	Kearsley-Fleet L; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., Klotsche J; Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany., van Straalen JW; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands., Costello W; iIrish Children's Arthritis Network (iCAN), Bansha, Co Tipperary, Ireland., D'Angelo G; Paediatrics, Ospedale Pediatrico G. Salesi di Ancona, Ancona., Giancane G; Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Horneff G; Department of Pediatrics, Asklepios Kinderklinik Sankt Augustin, Sankt Augustin.; Department of Pediatric and Adolescent Medicine, Medical Faculty, University Hospital of Cologne, Cologne, Germany., Klein A; Department of Pediatrics, Asklepios Kinderklinik Sankt Augustin, Sankt Augustin.; Department of Pediatric and Adolescent Medicine, Medical Faculty, University Hospital of Cologne, Cologne, Germany., Láday M; Pediatric Clinical Department 1, Spitalul Clinic Judetean De Urgenta, Tîrgu-Mureș, Romania., Lunt M; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK., de Roock S; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands., Ruperto N; Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy., Schoemaker C; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands.; Dutch JIA Patient and Parent Organisation (Member of ENCA), Rijen, The Netherlands., Vijatov-Djuric G; Faculty of Medicine, University of Novi Sad.; Department of Immunology, Allergology and Rheumatology, Institute for Child and Youth Health Care of Vojvodina, Novi Sad., Vojinovic J; Faculty of Medicine, Department of Pediatric Immunology and Rheumatology, University of Nis, University Clinic Center.; Department of Pediatric Rheumatology, Clinical Center Nis, Clinic of Pediatrics, Nis, Serbia., Vougiouka O; 'P a A Kyriakou' Children's Hospital, 2nd Paediatric Department, Athens University School of Medicine, Athens, Greece., Wulffraat NM; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands., Hyrich KL; Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.; NIHR Manchester BRC, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Minden K; Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.; Department of Pediatric Pulmonology, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Swart JF; Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2022 May 30; Vol. 61 (6), pp. 2524-2534.
DOI:	10.1093/rheumatology/keab641
Abstrakt:	Objectives: Burden of comorbidities are largely unknown in JIA. From 2000, national and international patient registries were established to monitor biologic treatment, disease activity and adverse events in patients with JIA. The aim of this analysis was to investigate in parallel, for the first time, three of the largest JIA registries in Europe/internationally-UK JIA Biologic Registers (BCRD/BSPAR-ETN), German biologic registers (BiKeR/JuMBO), multinational Pharmachild-to quantify the occurrence of selected comorbidities in patients with JIA. Methods: Information on which data the registers collect were compared. Patient characteristics and levels of comorbidity were presented, focussing on four key conditions: uveitis, MAS, varicella, and history of tuberculosis. Incidence rates of these on MTX/biologic therapy were determined. Results: 8066 patients were registered into the three JIA registers with similar history of the four comorbidities across the studies; however, varicella vaccination coverage was higher in Germany (56%) vs UK/Pharmachild (16%/13%). At final follow-up, prevalence of varicella infection was lower in Germany (15%) vs UK/Pharmachild (37%/50%). Prevalence of TB (0.1-1.8%) and uveitis (15-19%) was similar across all registers. The proportion of systemic-JIA patients who ever had MAS was lower in Germany (6%) vs UK (15%) and Pharmachild (17%). Conclusion: This analysis is the first and largest to investigate the occurrence of four important comorbidities in three JIA registries in Europe and the role of anti-rheumatic drugs. Combined, these three registries represent one of the biggest collection of cases of JIA worldwide and offer a unique setting for future JIA outcome studies. (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu